Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 11,393 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohorting Clear all

Conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Interventions: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 12
States / cities: Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more

Conditions: Healthy Participants
Interventions: CK-4021586, Placebo for CK-4021586; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Advanced Solid Tumors
Interventions: 2X-121 600 mg, 2X-121 800 mg, 2X-121 1000 mg, 2X-121 + 300 mg dovitinib, 2X-121 + 400 mg dovitinib, 2X-121 + 500 mg dovitinib; Drug · Combination Product
Lead sponsor: Allarity Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Huntersville, North Carolina • Cleveland, Ohio • Oklahoma City, Oklahoma

Conditions: Neurogenic Detrusor Overactivity
Interventions: Darifenacin; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 9
States / cities: San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more

Conditions: Melanoma
Interventions: APX005M, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, Hot Flashes
Interventions: .5% Bupivacaine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sacrum Fracture
Interventions: Not listed
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 13
States / cities: Indianapolis, Indiana • Boston, Massachusetts • Ann Arbor, Michigan + 10 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: placebo, Bowman-Birk inhibitor concentrate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Evaluation of Association Between Opiate Use and Biliary Dilation
Interventions: Endoscopic ultrasound; Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pancreatic Cancer
Interventions: Tolfenamic acid + gemcitabine + radiation; Drug
Lead sponsor: Orlando Health, Inc.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Peripheral Arterial Disease, Lower Extremity Arterial Disease
Interventions: EverFlex™ Self-Expanding Peripheral Stent System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 23
States / cities: Phoenix, Arizona • Modesto, California • Sacramento, California + 20 more

Conditions: Acute Lymphocytic Leukemia, Lymphoma
Interventions: Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Hepatitis B
Interventions: Vesatolimod, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Azacitidine, Lirilumab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Malaria
Interventions: Sanaria™ PfSPZ Vaccine, Chloroquine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: CNS Cancer, Head and Neck Cancer, GI Cancer, Gynecologic Cancer, Prostate Cancer, Thoracic Cancer, Breast Cancer
Interventions: Pencil Beam Scanning Proton Therapy; Radiation
Lead sponsor: The New York Proton Center; Other
Eligibility: 18 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelofibrosis, Indolent Systemic Mastocytosis
Interventions: TL-895, Placebo; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 6
States / cities: Aurora, Colorado • Rochester, Minnesota • Canton, Ohio + 3 more

Conditions: Concussion, Brain
Interventions: Screen time permitted, Screen Time Abstain; Behavioral
Lead sponsor: Theodore Macnow; Other
Eligibility: 12 Years to 25 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Advanced Solid Tumor
Interventions: CX-5461; Drug
Lead sponsor: Senhwa Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 6
States / cities: Santa Monica, California • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Lymphoma
Interventions: Ruxolitinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 10
States / cities: Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 6 more

Conditions: Carcinoma, Hepatocellular
Interventions: Onartuzumab, Sorafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Sarasota, Florida • Baltimore, Maryland • New York, New York + 2 more

Conditions: Peanut Allergy
Interventions: Peanut SLIT-tablet, Placebo; Biological · Other
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 4 Years to 65 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 33
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Chronic Wounds
Interventions: Swabs; Other
Lead sponsor: Systagenix Wound Management; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Psoriasis
Interventions: teplizumab; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Portland, Oregon

Search by objective public record fields.

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

(SGB) in Men Treated for Prostate Cancer Improve Hot Flashes

Study of Sacral Fractures Using Patient Based and Objective Outcomes

Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men

Opiate Use and Biliary Dilation

Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation

EverFlex Post Approval Study

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Sanaria™ PfSPZ Challenge Vaccine

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

The Effect of Screen Time on Recovery From Concussion

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma

Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Swab Sample Collection for the Detection of Bacterial Proteases

Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis